Device for delivery of rheumatoid arthritis medication
First Claim
Patent Images
1. A device for delivery of a rheumatoid arthritis drug across a dermal barrier, the device comprising:
- a microneedle and a plurality of nanostructures and microstructures projecting directly outward from a surface of the microneedle in a predetermined pattern, wherein at least a portion of the microstructures have a cross-sectional dimension of greater than about 500 nanometers and less than about 10 micrometers and a height of from about 20 nanometers to about 1 micrometer, and wherein at least a portion of the nanostructures have a cross-sectional dimension of less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5, wherein the microneedle further contains a channel; and
a reservoir that is in fluid communication with the channel of the microneedle and that contains a rheumatoid arthritis drug.
9 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are devices for delivering a rheumatoid arthritis drug across a dermal barrier. The devices include microneedles for penetrating the stratum corneum and also include structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The pattern of structures on the surface of the microneedles may include nano-sized structures.
200 Citations
30 Claims
-
1. A device for delivery of a rheumatoid arthritis drug across a dermal barrier, the device comprising:
-
a microneedle and a plurality of nanostructures and microstructures projecting directly outward from a surface of the microneedle in a predetermined pattern, wherein at least a portion of the microstructures have a cross-sectional dimension of greater than about 500 nanometers and less than about 10 micrometers and a height of from about 20 nanometers to about 1 micrometer, and wherein at least a portion of the nanostructures have a cross-sectional dimension of less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5, wherein the microneedle further contains a channel; and a reservoir that is in fluid communication with the channel of the microneedle and that contains a rheumatoid arthritis drug. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
-
29. A method for delivering a rheumatoid arthritis drug across a dermal barrier, the method comprising:
-
penetrating a stratum corneum with a microneedle having a surface on which a plurality of nanostructures and microstructures project directly outward therefrom in a predetermined pattern, wherein the microneedle further contains a channel, wherein at least a portion of the microstructures have a cross-sectional dimension of greater than about 500 nanometers and less than about 10 micrometers and a height of from about 20 nanometers to about 1 micrometer, and, wherein at least a portion of the nanostructures have a cross-sectional dimension of less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5, transporting a rheumatoid arthritis drug from a reservoir through the channel of the microneedle and across the stratum corneum. - View Dependent Claims (30)
-
Specification